This article is more than 5 years old. Information may no longer be current.
Envisia initiates phase 2a clinical trial for glaucoma treatment
Click Here to Manage Email Alerts
Envisia Therapeutics has initiated a phase 2a clinical trial of ENV515, a possible treatment for patients with glaucoma, the company announced in a press release.
The trial will investigate the tolerability and safety of the product.
According to the release, ENV515 is "a proprietary, fully biodegradable PRINT (particle replication in non-wetting templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular pressure reduction over as many as 6 months."
“We are excited to advance ENV515 into clinical development only a year after forming the company,” Neal Fowler, CEO at Envisia, said in the release. “The progress made with ENV515 underscores the power and flexibility of the PRINT technology to rapidly develop and advance promising product candidates, simultaneously, across multiple areas of interest in ophthalmology.”
“Poor patient compliance has long been a significant challenge in the treatment of glaucoma, making it a leading cause of preventable blindness in the U.S. today,” Steven L. Mansberger, MD, MPH, director of glaucoma services at Devers Eye Institute and the lead investigator for the ENV515 trial, said in the release. “Investigational products such as ENV515 have the potential to transform the treatment of glaucoma by removing compliance barriers and providing sustained reduction of intraocular pressure.”
As detailed in the release, the trial has been designed to be an open-label study that will assess 20 glaucoma patients at various sites in the U.S. Envisia expects results from the trial in mid-2015.